White Bagging, Brown Bagging, and the Pharmacist Caught in the Middle

Specialty drug distribution has never been a neutral topic, and the debate over white bagging and brown bagging has moved well past the boardroom. Twelve states have now passed laws banning mandatory white and brown bagging policies, and legislatures in a dozen more are actively debating the issue. Provider organizations from the American Medical Association (AMA) to the American Society of Clinical Oncology (ASCO) have taken formal positions against mandatory imposition. Pharmacists working in specialty access, infusion centers, and provider offices are navigating this conflict every day without a clear framework for where they stand.

What Do the Terms Mean?

Vocabulary matters because it shapes how patients and providers understand who controls the drug. White bagging refers to a mandatory policy in which a specialty pharmacy affiliated with the payer ships a medication directly to the hospital or physician's office for administration. Brown bagging goes one step further: the specialty pharmacy ships the medication directly to the patient, who then carries it to the provider for administration.¹ The traditional alternative is buy-and-bill, in which the provider purchases, stores, and administers the drug, then bills the payer for both the drug and the administration.

The financial logic driving white and brown bagging is straightforward. White bagging shifts coverage from the medical benefit to the pharmacy benefit, which typically allows greater access to manufacturer rebates. By facilitating direct shipments from specialty pharmacies to providers, payers can streamline distribution and negotiate better terms with manufacturers.²

What that framing leaves out is who absorbs the clinical and operational risk when the system breaks down.

Where Patient Safety Enters the Conversation

The clinical argument against mandatory white bagging is not theoretical. One of the primary concerns is its impact on care quality and safety. Shipping and processing issues cause delays that, for patients with serious or time-sensitive conditions, can result in severe health consequences. Many medications require precise dosing based on patient weight. Under a white-bagging mandate, providers lack the flexibility to adjust doses at the time of administration. They are forced to either delay treatment or administer suboptimal doses, both of which compromise patient outcomes.³

Oncology infusion illustrates the problem most sharply. Many patients with cancer are seen the same day as their scheduled infusion. Depending on laboratory test results and clinical presentation, initial treatment plans may be amended or cancelled altogether. When oncologists use CT scans, infusion regimens may need same-day adjustments based on disease progression. When the correct drug is not immediately available at the site of care, delays increase risk and can adversely impact outcomes.⁴

Drug waste adds a financial dimension that complicates the cost-savings argument payers use to justify the policy. If the drug is unsuitable for a patient because of dose adjustments related to changes in weight, treatment tolerance, adverse effects, or a complete alteration in treatment, the drug must be discarded. Specialty pharmacy policy explicitly prohibits the return of dispensed prescriptions. Payers are typically responsible for the cost of wasted vials under white bagging arrangements.⁵

The State Legislative Response

Providers and patient advocates have made meaningful progress at the state level. As of July 2025, 12 states have banned mandatory white bagging and brown bagging policies.¹

New Jersey's law, effective January 1, 2026, prohibits insurers from requiring step therapy for longer than 30 days for drugs treating multiple sclerosis or rheumatoid arthritis, allowing providers to authorize dispensation of the originally prescribed drug if treatment appears ineffective.^6,7 Connecticut has similar protections in its Medicaid program. Louisiana passed one of the earliest bans on white bagging after patient advocacy, while New York continues active legislative debate with multiple bills in recent sessions specifically addressing white and brown bagging restrictions.⁸

The AMA and ASCO have both issued formal opposition to mandatory imposition while making clear that voluntary white bagging arrangements, particularly those developed within integrated health systems, are a different matter.¹ The distinction between mandatory and voluntary is the fault line running through every piece of legislation on this issue.

Federal action has lagged. PBM reform bills in recent congressional sessions have addressed spread pricing, transparency, and formulary design, but distribution channel mandates have not been a primary focus. That gap leaves patients in states without protective legislation exposed to policies their providers may oppose but cannot unilaterally refuse.

The Pharmacist’s Role in This Landscape

Pharmacists occupy an unusual position in this debate. In specialty access and reimbursement roles, the daily work involves navigating the policies white bagging creates: prior authorization requirements tied to specific specialty pharmacies, site-of-care edits that redirect infusions away from provider offices, and the logistics of coordinating between a payer-designated specialty pharmacy and a provider office that may have its own formulary preferences.

Health system and specialty pharmacies continue to face mounting legal and operational challenges stemming from PBM contracting practices, below-cost reimbursement, 340B program restrictions, and mandatory white-bagging mandates. These challenges are reshaping the economics of care delivery and requiring proactive legal and compliance strategies to maintain access, reimbursement, and patient safety.⁸

A spring 2021 survey of Association of Community Cancer Centers members found that 87% of respondents said white bagging is an insurer mandate for some of their patients. Yet 59% said their cancer program or practice does not allow white bagging, citing dangerous treatment delays, patient safety concerns, unpredictable drug deliveries, and drug waste.⁹

Pharmacists who understand both the clinical and the contractual dimensions of these policies are positioned to do something most participants in this debate cannot: translate between the payer's cost logic and the provider's patient safety argument. That translation work involves helping provider offices document clinical necessity, escalate exceptions, and advocate for buy-and-bill when it serves the patient. This work is where pharmacist expertise converts directly into patient outcomes.

What to Watch

The legislative momentum at the state level shows no sign of slowing. Each new state ban narrows the geography in which mandatory white bagging remains enforceable and increases pressure on payers to reconsider blanket mandates. At the same time, payers continue expanding specialty pharmacy channel controls in commercial lines as a cost-management tool. The practical result is a patchwork of rules that varies by state, payer, and drug.

Pharmacists with deep knowledge of how these policies work, where exceptions exist, and how to navigate appeals will remain essential to patient access for the foreseeable future. Understanding the distinction between voluntary and mandatory white bagging, the state-by-state legal landscape, and the clinical rationale for provider-controlled dispensing positions specialty access professionals to advocate effectively on behalf of both patients and providers.

REFERENCES

1. Mandatory white bagging and brown bagging policies threaten patient access to care. American Medical Association, Association for Clinical Oncology. 2025. Accessed June 30, 2026. https://www.ama-assn.org/system/files/issue-brief-asco-patient-access-to-medication-safety.pdf

2. White, brown, clear, & gold bagging. Academy of Managed Care Pharmacy. June 27, 2024. Accessed June 30, 2026. https://www.amcp.org/legislative-regulatory-position/white-brown-clear-and-gold-bagging

3. White bagging fact sheet. National Infusion Center Association. November 4, 2024. Accessed June 30, 2026. https://infusioncenter.org/wp-content/uploads/2025/01/Fact-Sheet-White-Bagging-12-10-24.pdf

4. Health insurer specialty pharmacy policies threaten patient quality of care. American Hospital Association. March 2021. Accessed June 30, 2026. https://www.aha.org/system/files/media/file/2021/03/AOMarch8white-bagging-0221.pdf

5. Payer white-bagging requirements: considerations for access to infusion care. Avalere. June 2024. Accessed June 30, 2026. https://advisory.avalerehealth.com/wp-content/uploads/2024/06/Payer-White-Bagging-Requirements_Considerations-for-Access-to-Infusion-Care.pdf

6. NJ Rev Stat § 30:4D-7xx (2025). Accessed June 30, 2026. https://law.justia.com/codes/new-jersey/title-30/section-30-4d-7xx/

7. NJ Rev Stat § 52:14-17.28 (2025). Accessed June 30, 2026. https://law.justia.com/codes/new-jersey/title-52/section-52-14-17-28/?__cf_chl_f_tk=RnGITcL0NUXNNWI9ZrMW5MVjPzN3QsmFkpBtOMFZRZs-1782845040-1.0.1.1-MM2MImSwDOIwzSjGhmF7GILexX4e9wS95Ne0OGG3wmA

8. Dresser JC, Youssef B. Navigating PBM pressures, white bagging mandates, and 340B challenges: legal insights for health system pharmacies. Frier Levitt. October 23, 2025. Accessed June 30, 2026. https://www.frierlevitt.com/articles/navigating-pbm-pressures-white-bagging-mandates-and-340b-challenges-legal-insights-for-health-system-pharmacies/

9. How white bagging impacts patient care. Association of Cancer Cancer Centers. 2021. Accessed June 30, 2026. https://www.accc-cancer.org/policy-advocacy/white-bagging